A Parallel, Three Arm, Open-label, Multi-dose Pharmacokinetic Study of Dalfampridine-ER 7.5 mg Twice Daily in Both Healthy Volunteers and Those With Mild and Moderate Renal Impairment.

Trial Profile

A Parallel, Three Arm, Open-label, Multi-dose Pharmacokinetic Study of Dalfampridine-ER 7.5 mg Twice Daily in Both Healthy Volunteers and Those With Mild and Moderate Renal Impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2013

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 06 Nov 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
    • 02 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Sep 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top